Searching News Database: vascular disrupting agents
HSMN NewsFeed - 20 Mar 2015
OXiGENE, Inc. Announces $10 Million At-the-Market Registered Direct Offering
OXiGENE, Inc. Announces $10 Million At-the-Market Registered Direct Offering
HSMN NewsFeed - 21 Nov 2012
OXiGENE Announces OXi4503 Granted Orphan Designation for Treatment of Acute Myelogenous Leukemia
OXiGENE Announces OXi4503 Granted Orphan Designation for Treatment of Acute Myelogenous Leukemia
HSMN NewsFeed - 5 Apr 2010
OXiGENE Appoints Tamar D. Howson and Peter J. Langecker to Its Board of Directors
OXiGENE Appoints Tamar D. Howson and Peter J. Langecker to Its Board of Directors
HSMN NewsFeed - 11 Feb 2010
OXiGENE Announces Restructuring to Focus Resources on Key Programs and Provides Business Update
OXiGENE Announces Restructuring to Focus Resources on Key Programs and Provides Business Update
HSMN NewsFeed - 31 Dec 2007
OXiGENE Reports Positive Results in Phase 2 Study of ZYBRESTAT(TM) in Platinum-Resistant Ovarian Cancer
OXiGENE Reports Positive Results in Phase 2 Study of ZYBRESTAT(TM) in Platinum-Resistant Ovarian Cancer
Additional items found! 8
Members Archive contains
8 additional stories matching:
vascular disrupting agents
(Password required)
vascular disrupting agents
(Password required)
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!